Teriflunomide (Aubagio)


Indications for Prior Authorization:

Aubagio is a preferred disease modifying agent for the treatment of relapsing forms of multiple sclerosis when all the criteria below are met

Patients must meet the following criteria for the indication(s) above:

  • 18 years or older, AND
  • Diagnosis of relapsing multiple sclerosis confirmed by a neurologist, AND
  • None of these drugs may be used in combination with each other or any other disease modifying therapy including natalizumab (Tysabri), mitoxantrone (Novantrone), alemtuzumab or fingolimod (Gilenya), AND
  • Patient is not taking in combination with leflunomide, AND
  • Patient does not have severe hepatic impairment, AND
  • For females of child baring age: patient is not pregnant


  • 7 mg or 14 mg orally once daily
  • Rosuvastatin: the dose of rosuvastatin should not exceed 10mg once daily in patients taking Aubagio


  • Initial approval for one year
  • Renewal for one year if patient has clinical response

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar